Biotechnology

Asia Green Biotechnology Corp. Announces Extension of Management Cease Trade Order

May 10, 2024 5:55 PM

[NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES] CALGARY, AB / ACCESSWIRE / May 10, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company") (CSE:ASIA) announces that, further to its news releases dated April 17, 2024, April 26, 2024, and May 8, 2024, the Management Cease Trade Order ("MCTO") issued by the Alberta Securities Commission ("ASC") on May 08, 2024, remains in effect. The MCTO prohibits...

Read more

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

May 10, 2024 4:15 PM

TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an update on its business. During the quarter, the company expanded site selection activities for a Phase 3 study of its ARDS (Acute Respiratory...

Read more

Vibrant Wellness Announces UK Expansion, Elevating Personalized Health With Advanced Lab Technology

May 10, 2024 3:30 PM

This expansion marks a significant step towards advancing access to personalized care and longevity worldwide. SANTA CLARA, CA / ACCESSWIRE / May 10, 2024 / Vibrant Wellness, a CLIA-certified and CAP-accredited biotechnology company based in Santa Clara, CA, proudly announced their expansion in the UK. Vibrant is known for their extensive selection of specialty precision lab testing. The company combines biotechnology, innovative software...

Read more

Flightpath Biosciences Begins Human Clinical Testing of the World’s First Narrow-Spectrum Antibiotic Targeting Lyme Disease

May 10, 2024 10:00 AM

DETROIT, MI / ACCESSWIRE / May 10, 2024 / Flightpath Biosciences Inc., a clinical-stage life sciences company developing therapeutics to treat infectious diseases, announced today that the first healthy volunteer participants have been dosed in its Phase I clinical trial of FP-100 (hygromycin A), an orally-available, narrow-spectrum antimicrobial drug candidate. The single center, prospective, randomized, double-blind, placebo-controlled study...

Read more

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

May 10, 2024 8:30 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the first quarter of 2024 and provided a business update. "We have initiated several preclinical studies on the influence of DNase in combination with standard treatment paradigms such as chemotherapy or immune...

Read more

Ondine Biomedical Inc Announces ECDC Report Shows Rising HAIs and Antibiotic Use

May 10, 2024 2:00 AM

Non-regulatory announcement ECDC report shows HAIs are increasing antibiotic use A third of microorganisms causing HAIs (healthcare-associated infections) were found to be resistant to antibiotics, leaving doctors with fewer effective treatment options for patients VANCOUVER, BC / ACCESSWIRE / May 10, 2024 / Ondine Biomedical (LON:OBI): A recent report from the European Centre for Disease Prevention and Control (ECDC) helps underscore the need...

Read more

Renova Therapeutics Announces Strategic Focus and Roadmap Prioritization for Its Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus

May 8, 2024 9:00 PM

Renova Has Prioritized Two Primary Regulatory Pathways Where It Is Poised to Launch Pivotal Human Trials for Its Promising Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus CARLSBAD, CA / ACCESSWIRE / May 8, 2024 / Renova Therapeutics, a biotechnology company developing gene therapy-based treatments for cardiovascular and metabolic diseases, announced today that it has focused its development and commercialization efforts for...

Read more

enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 8, 2024 4:15 PM

- Ended the quarter with $42.9 million cash and investments on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025 - Positive 11-month topline efficacy data presented at the 46th Annual Charing Cross Symposium - Company on track to file PMA Application seeking VenoValve® FDA approval in Q4 2024 IRVINE, CA / ACCESSWIRE / May 8, 2024 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno"...

Read more

Introducing Cannovation Clinical Research Partners, LLC: Pioneering the Future of BioPharmaceutical Cannabinoid-Based Therapeutics

May 8, 2024 6:00 AM

Cannovation Clinical Research Partners, a pioneering Cannabis-Based Clinical Research Organization for Drug and Product Development, is proudly announcing its official launch, marking a significant milestone in pharmaceutical and biotech innovation. Founded by esteemed pharmaceutical and biotech executive Lisa Rich-Milan, alongside seasoned cannabis industry leader Michael Zaccaria, Cannovation aims to spearhead a revolution in medicine through...

Read more

NovAccess Global Advisory on Annual Meeting of Shareholders

May 7, 2024 11:25 AM

NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the postponement of its Annual Meeting of Shareholder which was previously scheduled to be held in May 2024. The Company expects to reschedule the annual meeting shortly. The Company previously announced that it would be hosting a virtual annual meeting of shareholders on May 6th, 2024 for shareholders of record as...

Read more

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

May 7, 2024 9:25 AM

STOCKHOLM, SE / ACCESSWIRE / May 7, 2024 / Vicore Pharma Holding (STO:VICO) The following resolutions were passed at the annual general meeting (the "AGM") of Vicore Pharma Holding AB (publ) on 7 May 2024. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance...

Read more

Form Bio Announces In Silico Assays, Enabling Gene Therapy Companies and Their Research Partners to Accelerate the Vector Discovery & Development Process

May 7, 2024 8:00 AM

New Capabilities Empower Gene Therapy Developers to Explore a Broader Range of Vector Designs and Rapidly Identify Candidates Best Poised for IND Speed and Success SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2024 / Form Bio, the provider of advanced computational life sciences technology, today announced the launch of In Silico Assays, a new set of capabilities for computationally screening vector designs prior to in vitro screening. In Silico...

Read more

Araceli Biosciences Introduces Matt Beaudet as New President and Chief Executive Officer

May 6, 2024 1:20 PM

PORTLAND, OR / ACCESSWIRE / May 6, 2024 / Araceli Biosciences, experts in cell-based screening and analysis technologies announced that their Board of Directors has appointed Matthew (Matt) Beaudet as the company's new CEO. Matt brings a distinguished career spanning over two decades in leadership across several influential companies in the biotech industry, such as Molecular Probes, Invitrogen, and Life Technologies, culminating in a...

Read more

Former Disney & Airbnb Executive Catherine Powell Joins Board for Psychedelic Biotech Company Inner State, Inc.

May 6, 2024 11:00 AM

LOS ANGELES, CA / ACCESSWIRE / May 6, 2024 / Inner State, Inc. (Inner State), a psychedelic biotech company dedicated to advancing women's health and wellness outcomes, appointed former Airbnb and Disney executive Catherine Powell to the Board of Directors. Inner State Board Member Catherine Powell "Catherine brings an extensive executive portfolio to Inner State's board and is recognized for her ability to manage complex operations at scale,"...

Read more

Resolutions at BioInvent's Annual General Meeting 2024

May 3, 2024 11:30 AM

LUND, SWEDEN / ACCESSWIRE / May 3, 2024 / BioInvent International (STO:BINV) The Annual General Meeting ("AGM") of BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) resolved to elect Laura Lassouw-Polman as new Board member, to re-elect the Board members Natalie Berner, Kristoffer Bissessar, Thomas Hecht, Leonard Kruimer, Nanna Lüneborg, Vincent Ossipow and Bernd Seizinger and to implement a long-term incentive program. The AGM...

Read more

Multiple Presentations at ASGCT 2024 Highlight Form Bio’s Expertise in AI-Based AAV Gene Therapy Design and Development

May 3, 2024 8:00 AM

Presentations Focused on How AI is Leveraged to Optimize Gene Therapy Construct Designs for Safety, Yield and Efficacy - Resulting in Faster Delivery to Market With a Higher Probability of Success SAN FRANCISCO, CA / ACCESSWIRE / May 3, 2024 / Form Bio, the breakthrough computational life sciences solutions provider, today announced that it will deliver multiple presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th...

Read more

Interim Report January-March 2024

May 3, 2024 2:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / May 3, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 3 2024- Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), publishes the interim report for first quarter 2024. Important events during the first quarter In January, Vicore announced discontinuation of the preclinical IMiD program to focus...

Read more

Enzolytics, Inc. Announces Formation of Marketing Company in Partnership with Third Coast Fulfillment

May 2, 2024 9:40 AM

ALLEN, TX / ACCESSWIRE / May 2, 2024 / Enzolytics, Inc. (OTC PINK:ENZC) (the "Company") announced today the plan to form ETC Marketing Inc. ("ETC Marketing") in partnership with Third Coast Fulfillment LLC ("TCF"), to serve the new ENZC initiative focusing on licensing of products in the medical devices, nutraceuticals, medical testing and other well being and safety products. The newly formed company, ETC Marketing, will be jointly owned with...

Read more

CARDIO inCode-Score (CIC-Score) Presentation at the European Society of Cardiology

May 1, 2024 10:00 AM

Preventive Cardiology Congress Athens 2024 OXFORD, ENGLAND / ACCESSWIRE / May 1, 2024 / GENinCode Plc, the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, gave details of a presentation by Kaiser Permanente at the European Society of Cardiology (ESC) Preventive Cardiology congress in Athens, Greece, on the ‘Joint consideration of low-density lipoprotein cholesterol ("LDL-C") and polygenic risk for...

Read more

NovAccess Global Announces New License to Advance its Immunotherapy Platform

April 30, 2024 9:00 AM

CLEVELAND, OH / ACCESSWIRE / April 30, 2024 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing a novel immunotherapy for patients suffering from cancers of the central nervous system, today announced the procurement of a new intellectual property license from Cedars-Sinai Medical Center to further advance the Company's immunotherapy platform. The license pertains to the use of Isocitrate Dehydrogenase-1 (IDH1), a protein...

Read more